65,437 trials
Hookworm Infection · Allergy
Primary: 100 Mcg/ml Na-ASP-2 Prick-puncture Skin Test — 0 Units on a scale
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
Breast Cancer · Non-small Cell Lung Cancer · Non-Hodgkins Lymphoma
Primary: Time to Reach Maximum Observed Plasma Concentration (Tmax) — 0.35; 0.34 hours
Acne Vulgaris
Primary: Mean Change From Baseline in Erythema at Weeks 1, 2, 4, 8, and 12 — 0.79; 0.76; 0.60; 0.47 units on a scale — p=0.9597
Catheterization
Primary: Clinician Overall Satisfaction With Catheter Securement — 2.27; 1.63 Units on a scale
Colorectal Cancer
Primary: Best Response (BR) — 0; 0; 6; 3 Participants
Cataract
Primary: Percent of Intraocular Pressure Spikes 30 mm Hg or Greater Postoperatively — 10.6; 7.6 percentage of participants
Schizophrenia
Primary: Change From Baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) Total Score up to 2 Hours After the First Intramuscular (IM) Injection…
Obstetric Labor Complications · Hemorrhage · Complications; Cesarean Section
Primary: Fibrinogen Level at 2 Hours After Delivery — 186; 418 mg/dL — p=<0.05
Schizophrenia and Predominant Negative Symptoms
Primary: Change From Open-label Baseline in Modified Scale for the Assessment of Negative Symptoms (SANS-18) Total Score at Week 10 Open-label Phase, Last Observation Carried…
Lung Cancer
Primary: Disease Status — 84; 78; 55; 54 percentage of participants
Hypercholesterolemia, Dyslipidemia
Primary: Arachidonic Acid Level After 2 Weeks of Treatment — 259.1; 269.6 nmol — p=0.455
Parkinson's Disease
Primary: Apathy Evaluation Scale (AES) — 19.6; 18.8; 17.9; 16.8 units on a scale
Schizophrenia · Schizoaffective Disorder
Primary: Change in Positive and Negative Syndrome Scale (PANSS) Score From the Beginning to the End of the Double-blind Treatment Phase Weeks 2-12 — 64; 68.13; 61.42; 66.32 units…
Diabetes Mellitus, Type 2
Primary: HbA1c Change From Baseline at Week 52 — -0.36; -0.57 Percent — p=0.0005